ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...

Description complète

Détails bibliographiques
Auteurs principaux:	Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators
Format:	Journal article
Langue:	English
Publié:	Wiley 2018

Documents similaires

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
par: Morgensztern, D, et autres
Publié: (2017)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
par: Morgensztern, D, et autres
Publié: (2018)

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
par: Talbot, D, et autres
Publié: (2018)

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
par: Govindan, R, et autres
Publié: (2017)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
par: Daniel Morgensztern, et autres
Publié: (2021-02-01)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
par: Ponce Aix, S, et autres
Publié: (2020)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
par: Corey J. Langer, et autres
Publié: (2018-07-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
par: Corey J. Langer, et autres
Publié: (2021-01-01)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
par: Eric Laille, et autres
Publié: (2015-01-01)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
par: Ajeet Gajra, et autres
Publié: (2018-07-01)

The uses of anxiety: Grace Abounding to the Chief of Sinners (1666)
par: Seymour, L
Publié: (2023)

Short Toxin-like Proteins Abound in Cnidaria Genomes
par: Michal Linial, et autres
Publié: (2012-11-01)

Misperceptions of "light" cigarettes abound: National survey data
par: Thomson George, et autres
Publié: (2009-05-01)

Aboundance, Diversity and Distribution of Ichthyoplanktons in Creeks and Coastal Waters of Khouzestan Province
par: S. Dehghan; A. Savari; P. Kochenin; J. Ghafle marammazi
Publié: (1999-01-01)

The Jurisdictional Basis, Elements and Remedies in the Action for Breach of Confidence - Uncertainty Abounds
par: Leo Tsaknis

Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
par: Christine E Orr, et autres
Publié: (2022-01-01)

Improbabilities abound”: Daphne du Maurier’s Rule Britannia and the speculative political future
par: Aoife Byrne
Publié: (2015-07-01)

Features of fibrosis regression abound in “non-cirrhotic” patients with resected hepatocellular carcinoma
par: Christine E. Orr, et autres
Publié: (2022-01-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
par: Véronique Hofman, MD, PhD, et autres
Publié: (2023-02-01)

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes
par: Garcia-Manero, G, et autres
Publié: (2021)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
par: Neda Stjepanovic, et autres
Publié: (2020-10-01)

Exodus, Psalms and Hebrews: A God abounding in steadfast love (Ex 34:6)
par: Alphonso Groenewald
Publié: (2008-03-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
par: Jun Sugisaka, et autres
Publié: (2023-11-01)

Ticks and Tick-Borne Pathogens Abound in the Cattle Population of the Rabat-Sale Kenitra Region, Morocco
par: Latifa Elhachimi, et autres
Publié: (2021-12-01)

Soils rich in biological ice-nucleating particles abound in ice-nucleating macromolecules likely produced by fungi
par: F. Conen, et autres
Publié: (2018-07-01)

Length Frequency, Sex Ratio and Relative Aboundance (CPUE) of Astacus leptoductylus in Arass Reservior (1997-98)
par: M. Karimpor; N. Hosseinpor
Publié: (1999-01-01)

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
par: Yoshimasa Shiraishi, et autres
Publié: (2022-09-01)

Computer processor unit 486
par: Universiti Teknologi Malaysia. Perpustakaan
Publié: (1989)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
par: Gridelli C, et autres
Publié: (2018-05-01)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
par: Siavash Rahimi MD, FRCPath, et autres
Publié: (2017-06-01)

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity
par: Hiroaki Ikawa, et autres
Publié: (2019-09-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
par: Daichi Fujimoto, MD, et autres
Publié: (2022-02-01)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
par: Hidetoshi Hayashi, et autres
Publié: (2011-01-01)

P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
par: Maria Amaya, et autres
Publié: (2023-08-01)

KIE 486 - KIMIA MAKANAN JUN 1994.
par: PPSK, Pusat Pengajian Sains Kimia
Publié: (1994)

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
par: Shreya Bhatia, BS, et autres
Publié: (2024-11-01)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
par: Lisa M. Hess, PhD, et autres
Publié: (2022-06-01)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
par: Laurent Greillier, et autres
Publié: (2016-10-01)

An Epidemiologic study of Oral and Pharyngeal Nonsquamous Cell Malignant Tumors inKerman province, Iran
par: MR. Zarei, et autres
Publié: (2007-03-01)

Glenn's Suzuki one-cylinder repair and tune-up guide : models 50 cc, 55 cc, 80 cc, 90 cc, 120 cc, 125 cc, 185 cc, 250 cc, 400 cc/
par: 402466 Crawford, Charles W., et autres
Publié: (1972)